Posted by Michael Wonder on 05 Jan 2026
MapLight Therapeutics receives fast track designation for ML-007C-MA for Alzheimer’s disease psychosis
5 January 2026 - MapLight Therapeutics today announced that the US FDA has granted fast track designation to ML-007C-MA, an investigational novel M1/M4 muscarinic agonist, for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis.
Enrollment is currently on-going in the Phase 2 VISTA study, a randomised, double-blind, placebo-controlled trial evaluating ML-007C-MA for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis.
